Pharmacology and Clinical Development of New Molecularly Targeted Agents
作者： Elisa Giovannetti , Elena Galvani
DOI: 10.1007/978-1-4939-2047-1_3
关键词: Cell signaling 、 Programmed cell death 、 Conventional chemotherapy 、 Cancer 、 Pharmacology 、 Angiogenesis 、 Tumor cells 、 Receptor 、 Medicine 、 Immune system
摘要: Conventional chemotherapy regimens have limited impact against most solid tumors. Recent advances in our understanding of the molecular basis cancer enabled development new, rationally designed, molecularly targeted antitumor agents. These agents interact with receptors, ligands, signaling molecules, or genes that play a pivotal role tumor transformation and growth, they can inhibit cell proliferation, induce programmed death, angiogenesis, enhance immune response.
springer.com
narcis.nl
vumc.nl参考文章(110)
Richard J. Pietras, David Gallardo, P. Nancy Wongvipat, H. Julie Lee, Joseph C. Poen, Dennis J. Slamon, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research. ,vol. 59, pp. 1347- 1355 ,(1999)
Hardman JG Ed, Goodman & Gilman's The Pharmacological Basis of Therapeutics ,(1985)
Bruce A. Chabner, Thomas G. Roberts, Chemotherapy and the war on cancer Nature Reviews Cancer. ,vol. 5, pp. 65- 72 ,(2005) , 10.1038/NRC1529
D.R. Alessi, Y. Saito, D.G. Campbell, P. Cohen, G. Sithanandam, U. Rapp, A. Ashworth, C.J. Marshall, S. Cowley, Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. The EMBO Journal. ,vol. 13, pp. 1610- 1619 ,(1994) , 10.1002/J.1460-2075.1994.TB06424.X
Horst Buerger, Frank Gebhardt, Hartmut Schmidt, Burkhard Brandt, Werner Boecker, Kirsten Hutmacher, Alf Beckmann, Ralph Lelle, Ronald Simon, Length and Loss of Heterozygosity of an Intron 1 Polymorphic Sequence of egfr Is Related to Cytogenetic Alterations and Epithelial Growth Factor Receptor Expression Cancer Research. ,vol. 60, pp. 854- 857 ,(2000)
Elena Galvani, Elisa Giovannetti, Francesca Saccani, Andrea Cavazzoni, Leticia G. Leon, Henk Dekker, Roberta Alfieri, Caterina Carmi, Marco Mor, Andrea Ardizzoni, Pier Giorgio Petronini, Godefridus J. Peters, Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Neoplasia. ,vol. 15, pp. 61- 72 ,(2013) , 10.1593/NEO.121434
Fabrice Andre, Dominique Grunenwald, Jean-Pierre Pignon, Antoine Dujon, Jean Louis Pujol, Pierre Yves Brichon, Laurent Brouchet, Elisabeth Quoix, Virginie Westeel, Thierry Le Chevalier, Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications Journal of Clinical Oncology. ,vol. 18, pp. 2981- 2989 ,(2000) , 10.1200/JCO.2000.18.16.2981
Ding Wang, Scott A. Boerner, James D. Winkler, Patricia M. LoRusso, Clinical experience of MEK inhibitors in cancer therapy Biochimica et Biophysica Acta. ,vol. 1773, pp. 1248- 1255 ,(2007) , 10.1016/J.BBAMCR.2006.11.009
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609